A retrospective, cross-sectional study identifying patient level drivers of physicians decisions to prescribe a ditan or gepant in patients with acute migraine treatment
Latest Information Update: 01 Aug 2021
At a glance
- Drugs Lasmiditan (Primary) ; Rimegepant (Primary) ; Ubrogepant (Primary)
- Indications Migraine
- Focus Therapeutic Use
- 01 Aug 2021 New trial record
- 06 Jun 2021 Results presented at the 63rd Annual Scientific Meeting of the American Headache Society